Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb. Deucravacitinib was approved for medical use in the United States in September 2024, and in Australia in December 2024. The US Food and Drug … WebBrand Names: US Sotyktu What is this drug used for? It is used to treat plaque psoriasis. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; …
First de novo deuterated drug poised for approval - Nature
WebFeb 26, 2024 · Deucravacitinib Brand name: Sotyktu Drug class: Skin and Mucous Membrane Agents, Miscellaneous Chemical name: 6- (cyclopropanecarbonylamido)-4- [2-methoxy-3- (1-methyl-1,2,4-triazol-3-yl)anilino]-N- (trideuteriomethyl)pyridazine-3-carboxamide Molecular formula: C 20 H 19 D 3 N 8 O 3 CAS number: 1609392-27-9 WebCompare prices and print coupons for Deucravacitinib (Sotyktu) and other drugs at CVS, Walgreens, and other pharmacies. ... Apps GoodRx Prescription Discount Card Drugs A-Z Drugs by Health Conditions Drug Classes Most Prescribed Drugs GoodRx for Pets Brand-Name Drugs GoodRx Gold ... GoodRx is not sponsored by or affiliated with any of the … difference between purging and blanketing
Bristol Myers Squibb’s Applications for Deucravacitinib for the ...
WebAug 16, 2024 · Drug. Sponsors. Properties (parent molecule) Lead indication. Status. De novo. Deucravacitinib. Bristol Myers Squibb. TYK2 inhibitor. Plaque psoriasis. NDA. PHA-022121 WebNov 29, 2024 · Generic name: deucravacitinib (due krav a sye ti nib) Brand name: Sotyktu. Dosage form: oral tablet (6 mg) Drug class: Multikinase inhibitors. Medically … WebApr 7, 2024 · The drug, to be marketed under the brand name Sotyktu, is aimed at patients who are candidates for systemic therapy or phototherapy and is not recommended in combination with other potent immunosuppressants. form 2 headphones